The Procter & Gamble (PG) CEO Jejurikar Sells $5.7M of Stock
Key Points
- Shailesh Jejurikar's sale of 35,000 shares reduced his ownership by about 38.7%, leaving him with approximately 55,391 shares.
- Procter & Gamble closed at $161.02 on the day of the sale and has recently traded around $158.99, which is about 1.3% below that closing price.
- Analysts have a consensus 'buy' rating for Procter & Gamble, with a mean price target of $172.35, reflecting potential upside from the recent trading levels.
Get The Procter & Gamble Company text alerts
We text you when insiders, Congress, analysts or big funds move on $PG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated The Procter & Gamble Company alert may contain errors. Disclosures
On October 23, 2026, Shailesh Jejurikar, Chairman, President, and CEO of The Procter & Gamble Company, sold 35,000 shares for approximately $5.7 million. This sale was reported in a Form 4 filing with the SEC. Following this transaction, Jejurikar owns about 55,391 shares, which is a reduction of about 38.7% from his previous holdings.
Jejurikar sold his shares at an average price of $163.09. The stock closed at $161.02 on the same day, suggesting the sale happened near that closing price. Recently, the stock has traded around $158.99, which is about 1.3% below the event close.
PG
The Procter & Gamble Company
Other Institutional Activity in Procter & Gamble
Capital Investment Advisors increased its position by 17,061 shares, bringing its total to 462,434 shares valued at about $67.2 million. Mutual of America Capital Management also raised its stake by 13,546 shares, resulting in 253,659 shares worth approximately $36.9 million. Conversely, Wilmington Savings Fund Society reduced its holdings by 18,433 shares, ending with 315,785 shares valued at around $45.9 million.
The Procter & Gamble Company Stock Down 3.4%
Procter & Gamble shares are currently trading below their 52-week high of $167.25 and are above their 200-day moving average by about 7.1%. The stock's recent price of $158.99 is approximately 4.9% below its 52-week high and 15.5% above its 52-week low of $137.62. Analysts have set a mean price target of $172.35, indicating potential upside.
Recent Earnings
For the trailing twelve months, Procter & Gamble reported revenue of about $87.9 billion and earnings per share of $6.64. The company has demonstrated a revenue growth of 4.0% year-over-year and a net margin of 18.2%. The next earnings report is expected on January 21, 2027.
Insider Buying and Selling at The Procter & Gamble Company
In addition to Jejurikar's sale, Balaji Purushothaman, Chief Human Resources Officer, sold 4,181 shares on the same day for about $671,928. Paul Gama, CEO of Health Care, also sold 4,331 shares for approximately $698,460. Earlier, on October 5, officers Paul Gama and Susan Street Whaley sold 2,225 and 2,369 shares, respectively.
Analysts Set New Price Targets
On October 23, 2026, several analysts updated their ratings on Procter & Gamble. Freedom Broker upgraded the stock to a 'Buy' rating with a target of $176. UBS maintained its 'Buy' rating but raised its price target to $190. Citigroup also kept its 'Buy' rating, increasing its target to $187. BNP Paribas and JP Morgan maintained their ratings, with targets of $189 and $180, respectively.
About Procter & Gamble
The Procter & Gamble Company provides a wide range of branded consumer goods globally. It operates in various segments, including Beauty, Grooming, Health Care, and Household Care. The company has a strong market presence and continues to innovate in its product offerings.
Bottom Line
Investors should watch for Procter & Gamble's next earnings report on January 21, 2027, and keep an eye on further insider transactions. Jejurikar's recent sale highlights ongoing activity among company executives as they adjust their holdings amidst a fluctuating stock price.
Related Filing Alerts
Source: Shailesh Jejurikar's Form 4 filing on $PG (Oct 23, 2026). Written by software, not financial advice. How we make alerts